Alizadeh Lab
Our group's research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies.
Our group develops and applies genomic biomarkers of tumor cells, whether detected through biopsy of the primary neoplasm, or noninvasively through monitoring of the bodily fluids including blood. We apply such genomic biomarkers for the early detection, diagnosis, and monitoring of diverse tumors including lymphomas and solid tumors.
We are also interested in better molecular understanding of normal tissue stem cells and their malignant tumor-initiating counterparts (cancer stem cells), toward identification of the underlying mechanisms relevant to specific cancers of the hematopoietic system. These tumors include follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma.
We have also worked to build prognostic and predictive models for clinical and therapeutic outcomes of diverse human malignancies, through large-scale bioinformatic meta-analysis of human tumor transcriptomes, including deconvolution of complex tumor admixtures including infiltrating leukocytes.
In this effort, we help build and employ tools from functional genomics, computational biology, molecular genetics, and mouse models. We are applying this knowledge toward the design of clinical trials in the treatment of patients with various malignancies, whom I care for directly or indirectly, as a clinician specializing in Medical Oncology and Hematology.
Legacy site on HEEBO/MEEBO microarrays, click here
Our Work in the News
Activity in Genes, Immune Cells Tied to Cancer Survival in Study
[US News & World Report]
Chance of surviving cancer is written in our GENES: Doctors develop database which predicts how long a person will live based on their DNA
[Daily Mail (UK)]
Genomic Signatures for Integrative Models of Clinical Heterogeneity in Patients with Follicular Lymphoma
[CDMRP Department of Defense]
Identifying relapse in lymphoma patients with circulating tumor DNA [Stanford Medicine Scope Blog]
New way to sort cells without limitations of traditional methods [Stanford Medicine News Center]
Smoking gun or hit-and-run? How oncogenes make good cells go bad [Stanford Medicine Scope Blog]
Damon Runyon Cancer Research Foundation Awards over $4M to 10 Top Young Clinical Investigators [Damon Runyon CRF]
Blood test could provide rapid, accurate method of detecting solid cancers [Stanford Medicine]
New ultrasensitive blood test can detect cancer [Examiner.com]
Tumor Type Targeted Sequencing Method Picks Up Personalized Circulating Tumor DNA Markers [In Sequence]